A total of 244 patients were included in the study, of whom 224 (92%) were previous injecting drug users. Major DDIs were found for: paritaprevir-r/ombitasvir plus dasabuvir (3D), in 60 (44%) of 138 individuals with genotype 1; paritaprevir-r/ombitasvir (2D), in 22 (37%) of 60 individuals with genotype 4; sofosbuvir/ledipasvir (SOF/LDV), in four (2%) of 198 patients with genotype 1 or 4; simeprevir (SMV) plus SOF, in 160 (81%) of 198 patients with genotype 1 or 4; daclatasvir (DCV) plus SOF, in seven (3%) of 244 patients with genotype 1, 3 or 4 (P < 0.001). Minor DDIs were found for: 3D, in 123 (89%) individuals with genotype 1; 2D, in 52 (87%) individuals with genotype 4; SOF/LDV, in 154 (78%) patients with genotype 1 or 4; SMV plus SOF, in 129 (65%) patients with genotype 1 or 4; DCV plus SOF, in 149 (61%) patients with genotype 1, 3 or 4 (P < 0.001).
Introduction
The current standard of care for treatment of hepatitis C virus (HCV) infection is a combination of two or more direct-acting antivirals (DAAs) against HCV [1, 2] . All oral DAA regimens usually provide a sustained virological response (SVR) for more than 90% of patients [1] [2] [3] [4] [5] , with only the possible exception of patients with cirrhosis and HCV genotype 3 infection [6] . The increased virological potency coupled with the excellent tolerability of all oral DAA regimens are driving their use in many patients previously excluded from interferon-based therapies. In this regard, persons who inject drugs (PWID) were frequently not considered candidates for treatment of HCV infection. As PWID usually have psychiatric disorders [7] , lack of tolerance to interferon and potential nonadherence were the main concerns. HIV coinfection was usually an additional issue in PWID. Thus, lower cure rates for HIV/HCV genotype 1 coinfection were obtained with peg-interferon plus ribavirin [8] [9] [10] and with combinations including telaprevir or boceprevir [11] .
All HIV-infected patients should be treated with antiretroviral therapy (ART), according to recent evidence [12] . Thus, drugÀdrug interactions (DDIs) between DAAs and ART need to be addressed in the overwhelming majority of HIV/HCV-coinfected candidates for treatment of HCV infection [1, 2] . Changing ART because of potential DDIs with DAAs is usually feasible. However, switching one drug of an effective ART regimen is not always free of the risk of virological failure [13] , and adverse events caused by the newly introduced drug are an obvious hazard [13] [14] [15] . In addition, central nervous system (CNS)-acting drugs, commonly prescribed in HIV/HCVcoinfected PWID, may be more difficult to discontinue. In view of these issues, we analysed the frequency and degree of potential DDIs between DAAs and concomitant medication used by HIV/HCV-coinfected patients, including ART and other drugs.
Patients and methods

Design
All patients with HIV infection attending our unit, an infectious diseases unit in a tertiary care centre in southern Spain, were included in a prospective cohort study. This was a cross-sectional analysis of patients from this cohort who attended the out-patient clinic of this unit at least once from November 2014 to November 2015. Individuals with viraemic infection with HCV genotype 1, 3 or 4 were included in the study. Patients were excluded if treatment of HCV infection had been started before the study period.
Evaluation of antiretroviral drugs and other medication
Patients were routinely asked at every visit whether they were receiving concomitant medication, for any drugs prescribed by other physicians in addition to ART. All medications used by the patients included in the cohort were recorded in a database. For the present study, electronic prescription records were examined to review and, if necessary, update active medications. All antiretroviral drugs are prescribed to patients using an electronic prescription tool linked to the hospital pharmacy. All antiretroviral drugs are dispensed by the hospital pharmacy, which also keeps a record of them. Common medications are subject to compulsory electronic prescription for patients attending for care within the Andalusian Health System. Each person holding an electronic prescription card for the Andalusian Health System has a searchable history of current and past medications. Self-referred use of heroine, cocaine or cannabis was recorded at every visit in the cohort. Antiretroviral drugs and commonly prescribed medications were grouped following the University of Liverpool database categories (http://www.hep-druginteractions.org).
Classification of DDIs
DDIs were classified following the University of Liverpool database (http://www.hep-druginteractions.org) criteria. This database was last accessed in July 2016. Potential DDIs between currently available DAAs and concomitant medications, including individual antiretroviral drugs, were evaluated in every patient at the last follow-up visit. The interferon-free regimens analysed were those with activity against HCV genotype 1, 3 or 4, and currently recommended by guidelines [1, 2] . Thus, the regimens evaluated were: (i) sofosbuvir plus simeprevir (SOF + SMV); (ii) SOF plus daclatasvir (SOF + DCV); (iii) SOF plus ledipasvir (SOF/LDV); (iv) ritonavir-boosted paritaprevir/ombitasvir plus dasabuvir (3D); (v) ritonavirboosted paritaprevir/ombitasvir (2D).
DDIs were classified as (i) absent: no significant DDI is expected; (ii) minor DDI: concomitant administration of these particular drugs may require close monitoring, alteration of the drug dosage or alteration of the timing of administration; (iii) major DDI: the specific drugs should not be co-administered; (iv) classification is not possible: no data with which to classify DDIs.
Ethics
This study was conducted according to the principles of the declaration of Helsinki. The local ethics committee approved the collection of data associated with the cohort. All patients gave their informed consent at inclusion in the cohort.
Results
Characteristics of the study patients
Of 426 patients with HIV infection who were seropositive for anti-HCV antibodies followed in our unit during the study period, 244 fulfilled the inclusion criteria. They were mostly PWID. One hundred and 38 patients (57%) were coinfected with HCV genotype 1. The main characteristics of the patients at the date of evaluation are summarized in Table 1 .
The absolute number of individual antiretroviral drugs prescribed to the study patients was 504. The number of antiretroviral agents by drug category is show in Table 2 .
The median (range) number of antiretroviral drugs per patient was 3 (0-6). One hundred and 81 patients (81%) were on three-drug ART regimens. Thirteen individuals (6%) were taking ritonavir-boosted protease inhibitors as monotherapy. Twenty-two patients (10%) were not taking ART. Common medications consisted of 889 drugs. The number of medications by drug class is shown in Table 3 . The median (range) number of common medications per patient was 4 (0-13). Seventy-four individuals (33%) used one to three common medications, 67 (30%) used four to six, 38 (17%) used seven to nine and 16 (7%) used 10 or more.
Frequencies of potential DDIs
Potentially significant DDIs were observed in most patients. Potential minor DDIs were observed in 220 individuals (98%). Potential major DDIs were detected in 190 patients (85%). Globally, potential DDIs of any severity were found in 132 (96%) of 138 HCV genotype 1-infected patients for 3D, in 60 (100%) HCV genotype 4-infected patients for 2D, in 154 (78%) of 198 
2D, paritaprevir-r/ombitasvir; 3D, paritaprevir-r/ombitasvir plus dasabuvir; DCV, daclatasvir; LDV, ledipasvir; SMV, simeprevir; SOF, sofosbuvir. Minor DDI: drugs may require close monitoring, alteration of drug dosage or alteration of the timing of administration. Major DDI: drugs should not be co-administered. 3D only applies to hepatitis C virus (HCV) genotype 1 (n = 138). 2D only applies to HCV genotype 4 (n = 60). SOF/LDV and SMV plus SOF may be used in both HCV genotypes 1 and 4 (n = 198). DCV plus SOF may be used in HCV genotypes 1, 3 and 4 (n = 244).
individuals with HCV genotype 1 or 4 infection for SOF/LDV, in 182 (92%) of 198 patients with HCV genotype 1 or 4 infection for SMV plus SOF, and in 136 (61%) of 224 subjects for DCV plus SOF. The frequencies of potential minor and major DDIs by each regimen are summarized in Figure 1 . Regarding ART, the drug classes most frequently involved in potential DDIs were HIV protease inhibitors, followed by non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) ( Table 2 ). Potential DDIs affecting HIV protease inhibitors were mainly associated with regimens including HCV protease inhibitors. NNRTIs showed potential DDIs across every anti-HCV regimen. NRTIs were frequently involved in potential DDIs with SOF/ LDV, because of the high percentage of patients on tenofovir/emtricitabine.
A high proportion of patients used common medications with potential for DDIs with DAAs. Thus, 120 individuals (54%) were exposed to CNS-acting drugs. Anxiolytics were used by 109 patients (49%), antidepressants by 44 (20%), anticonvulsants by 27 (12%), and antipsychotics by 18 (8%). Within CNS-acting drugs, anxiolytics frequently had potential DDIs with 3D, 2D and SOF plus SMV (Table 3) . Anticonvulsants were associated with major DDIs in a small proportion of patients for every DAA combination. Eighty-nine patients (40%) were receiving gastrointestinal agents, 57 (64%) of whom were taking omeprazole. Five patients (2%)patients, three infected with HCV genotype 1 and two with HCV genotype 4, were using medications without available data on DDIs in the Liverpool database. Nine individuals (3.7%) were receiving common medications that did not correspond to any category listed in Table 3 . None of them were associated with minor or major DDIs.
Regarding the use of illegal drugs, a small proportion of patients self-referred drug consumption. Thus, 19 individuals (8.5%) acknowledged current use of heroin, 15 patients (6.7%) reported smoking or snorting cocaine, and 25 patients (11%) reported smoking cannabis. Twenty (10%) candidates to receive 2D, 3D or SOF plus SMV, those with genotype 1 or 4 infection, could have potential minor DDIs with heroin, cocaine or cannabis. 
Hypertension/heart failure agents
2D, paritaprevir-r/ombitasvir; 3D, paritaprevir-r/ombitasvir plus dasabuvir; DCV, daclatasvir; LDV, ledipasvir; SMV, simeprevir; SOF, sofosbuvir. Minor DDI: drugs may require close monitoring, alteration of drug dosage or alteration of the timing of administration. Major DDI: drugs should not be co-administered. 3D only applies to HCV genotype 1 (n = 138). 2D only applies to HCV genotype 4 (n = 60). SOF/LDV and SMV plus SOF may be used in both HCV genotypes 1 and 4 (n = 198). DCV plus SOF may be used in HCV genotypes 1, 3 and 4 (n = 244).
Discussion
We found that potential major DDIs (i.e. drugs should not be co-administered) and minor DDIs (i.e. drugs may require some sort of management to be co-administered) were more prevalent for 3D, 2D and SMV plus SOF. These interactions were mainly related to HIV protease inhibitors and CNS-acting drugs. DDIs between regimens currently recommended to treat HCV infection and ART or commonly prescribed medications are very frequent among HIV/HCV-coinfected patients. Previous studies on DDIs between DAAs and comedications among HIV/HCV-coinfected patients focused on ART [16] [17] [18] . In a large study on HIV/HCV coinfection in France, potential DDIs between DAAs currently available in that country and individual antiretroviral drugs were evaluated [16] . Lower rates of DDIs than in the present study were found. For example, one-third of the patients would have had contraindications to use 3D in France [16] , whereas we found a frequency 10% higher. Moreover, there were larger differences in the proportion of patients with potential DDIs. In the present study, potential minor DDIs were observed across all DAA regimens, ranging from 59 to 88%. In the study by Poizot-Martin et al. [16] , SOF/LDV, among the currently recommended DAAs, showed the highest frequency of minor DDIs, involving two-thirds of the patients. The rates of DDIs observed in other studies analysing DDIs between DAAs and ART in HIV/HCV coinfection show similar differences with those reported in the present study [17, 18] . The main reason for the higher rates of DDIs identified in the present study compared with previous studies is likely to be the inclusion of both ART and comedications. Given the increasing number and complexity of comedications in HIV-infected patients as they age, DDIs between DAAs and both ART and concomitant drugs should be carefully evaluated in every candidate for HCV treatment.
This study may have a few limitations. First, underreporting of concomitant common drugs cannot be ruled out. In particular, no registry can account for over-thecounter medication. In spite of this, the majority of drugs taken by HIV/HCV-coinfected patients in Andalusia, southern Spain, are recorded in electronic prescriptions. Thus, ART dispensation is centralized in hospital pharmacies and common medications are subject to compulsory electronic prescription. Both in-hospital and regional databases of electronic prescriptions were queried for the present study. These are strengths of our study. Secondly, we did not fully analyse illicit recreational drug use. The assessment of those drugs is complicated by self-reporting. Cannabis is widely smoked by former PWID in our area, and its use was probably underreported by the study patients. Tetrahydrocannabinol levels may be increased by concomitant use of ritonavir or simeprevir [1] . However, co-administration of 3D or SMV along with cannabis in the study patients is unlikely to lead to major issues, as two-thirds of them were previously exposed to ritonavir-boosted HIV protease inhibitors without signs of cannabis intoxication. In contrast, use of psychostimulants, such as amphetamines, can lead to fatal consequences without warning in patients taking ritonavir [19] .
The global epidemic of HCV infection has been estimated at 160 million individuals world-wide [1] . In the favourable scenario of high response rates associated with all oral DAAs, patients not achieving SVR may be a small proportion of those treated. If all viraemic HCV infections were treated using the current standards of therapy, approximately 16 million patients would not achieve an SVR. These individuals could represent a difficult challenge, as the selection of viral variants associated with resistance severely limits future treatment options, particularly for NS5A inhibitors [20, 21] . Thus, every effort should be made to prevent virological failure. DDIs might be the cause underlying some relapses, as recently reported for proton pump inhibitors and SOF/LDV [22] . Careful assessment of all concomitant medications before starting anti-HCV therapy should be undertaken. Drugs potentially associated with DDIs should be stopped and, if necessary, replaced. If this is not possible an alternative DAA combination should be considered.
In summary, a high proportion of HIV/HCV-coinfected patients are prescribed drugs with the potential for relevant DDIs with current DAA combinations. It is usually possible to address DDIs with ART switching to an alternative regimen. However, concurrent non-ART medications may be more difficult to change, particularly CNS sedative drugs taken by former or current PWID, or to control, as in the case of antacids and other over-thecounter medicines. Clinicians managing HIV/HCV coinfection should actively assess comedications before selecting a DAA combination to treat HCV infection.
